In the brain, HT significantly decreased expression of pro-inflammatory cytokine IL-18, and cytokines with dual roles IL-6, and IFN-γ, 1 h after therapy was initiated (Figures 5c,f,g). The gene discussed is IL6; the disease is hematocrit.